Conmed Corp Financials
This page shows Conmed Corp (CNMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash flow stayed sturdy even as selling costs reset margins lower, leaving CONMED more cash-generative than earnings suggest.
FY2025 looked less like a demand problem than a cost-structure problem: from FY2024, revenue added$68M while operating income lost$98M . With operating cash flow still at$171M and gross margin at54.6% , the squeeze appears concentrated in overhead rather than core product economics.
The business remained light on capital spending: capex was only
The balance sheet is de-risking gradually, with debt-to-equity improving to 0.8x from 1.2x in FY2023, so borrowing is a smaller part of the capital structure than it was two years ago. But
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Conmed Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Conmed Corp has an operating margin of 7.5%, meaning the company retains $7 of operating profit per $100 of revenue. This strong profitability earns a score of 69/100, reflecting efficient cost management and pricing power. This is down from 15.3% the prior year.
Conmed Corp's revenue grew 5.2% year-over-year to $1.4B, a solid pace of expansion. This earns a growth score of 51/100.
Conmed Corp has elevated debt relative to equity (D/E of 0.85), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 11/100, reflecting increased financial risk.
Conmed Corp's current ratio of 2.10 indicates adequate short-term liquidity, earning a score of 60/100. The company can meet its near-term obligations, though with limited headroom.
Conmed Corp converts 11.0% of revenue into free cash flow ($150.9M). This strong cash generation earns a score of 69/100.
Conmed Corp's ROE of 4.7% shows moderate profitability relative to equity, earning a score of 60/100. This is down from 13.8% the prior year.
Conmed Corp scores 1.85, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Conmed Corp passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Conmed Corp generates $3.62 in operating cash flow ($170.7M OCF vs $47.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Conmed Corp earns $3.3 in operating income for every $1 of interest expense ($102.6M vs $31.1M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Conmed Corp generated $1.4B in revenue in fiscal year 2025. This represents an increase of 5.2% from the prior year.
Conmed Corp's EBITDA was $155.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 38.4% from the prior year.
Conmed Corp reported $47.1M in net income in fiscal year 2025. This represents a decrease of 64.4% from the prior year.
Conmed Corp earned $1.51 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 64.5% from the prior year.
Cash & Balance Sheet
Conmed Corp generated $150.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 2.0% from the prior year.
Conmed Corp held $38.9M in cash against $834.2M in long-term debt as of fiscal year 2025.
Conmed Corp paid $0.60 per share in dividends in fiscal year 2025. This represents a decrease of 25.0% from the prior year.
Conmed Corp had 31M shares outstanding in fiscal year 2025. This represents a decrease of 0.2% from the prior year.
Margins & Returns
Conmed Corp's gross margin was 54.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the prior year.
Conmed Corp's operating margin was 7.5% in fiscal year 2025, reflecting core business profitability. This is down 7.9 percentage points from the prior year.
Conmed Corp's net profit margin was 3.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 6.7 percentage points from the prior year.
Conmed Corp's ROE was 4.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.1 percentage points from the prior year.
Capital Allocation
Conmed Corp invested $55.9M in research and development in fiscal year 2025. This represents an increase of 2.7% from the prior year.
Conmed Corp invested $19.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 51.4% from the prior year.
CNMD Income Statement
| Metric | Q2'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $317.0M-15.0% | $373.2M+10.4% | $337.9M-1.3% | $342.3M+6.6% | $321.3M-7.1% | $345.9M+9.2% | $316.7M-4.6% | $332.1M |
| Cost of Revenue | $133.6M-13.8% | $154.9M-9.8% | $171.8M+11.5% | $154.0M+7.3% | $143.5M-2.8% | $147.6M+7.2% | $137.7M-7.2% | $148.4M |
| Gross Profit | $183.4M-16.0% | $218.3M+31.4% | $166.1M-11.8% | $188.3M+5.9% | $177.8M-10.4% | $198.3M+10.8% | $179.0M-2.6% | $183.7M |
| R&D Expenses | $16.3M+9.6% | $14.9M+7.2% | $13.9M-1.7% | $14.1M+9.2% | $12.9M-1.7% | $13.2M-2.8% | $13.6M-3.8% | $14.1M |
| SG&A Expenses | $141.7M-15.0% | $166.8M+18.8% | $140.3M+3.2% | $136.0M-8.6% | $148.8M+12.2% | $132.7M+33.0% | $99.7M-18.6% | $122.5M |
| Operating Income | $25.4M-30.6% | $36.6M+208.3% | $11.9M-68.9% | $38.2M+139.1% | $16.0M-69.6% | $52.5M-20.1% | $65.7M+39.5% | $47.1M |
| Interest Expense | $7.1M-4.2% | $7.4M-3.1% | $7.6M-2.8% | $7.8M-5.6% | $8.3M-6.5% | $8.9M-4.3% | $9.3M-3.6% | $9.6M |
| Income Tax | $4.5M-63.8% | $12.5M+785.0% | $1.4M-83.4% | $8.5M+419.4% | $1.6M-83.5% | $9.9M+32.3% | $7.5M-0.9% | $7.5M |
| Net Income | $13.8M-17.6% | $16.8M+487.1% | $2.9M-86.7% | $21.4M+254.9% | $6.0M-82.1% | $33.7M-31.1% | $49.0M+63.4% | $30.0M |
| EPS (Diluted) | $0.45 | N/A | $0.09-87.0% | $0.69+263.2% | $0.19 | N/A | $1.57+63.5% | $0.96 |
CNMD Balance Sheet
| Metric | Q2'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3B-0.5% | $2.3B+0.1% | $2.3B-0.3% | $2.3B+1.3% | $2.3B-0.4% | $2.3B-0.4% | $2.3B+1.3% | $2.3B |
| Current Assets | $670.6M-0.3% | $672.9M+1.6% | $662.2M+0.7% | $657.8M+2.9% | $639.0M-0.2% | $640.0M-0.2% | $641.0M+2.8% | $623.8M |
| Cash & Equivalents | $35.0M-14.2% | $40.8M+4.8% | $38.9M+14.7% | $33.9M-4.4% | $35.5M+45.1% | $24.5M-36.4% | $38.5M+33.2% | $28.9M |
| Inventory | $366.1M+3.0% | $355.5M-2.4% | $364.4M+0.6% | $362.3M+2.1% | $354.7M+2.3% | $346.7M+1.2% | $342.6M+6.3% | $322.4M |
| Accounts Receivable | $228.7M-7.7% | $247.8M+10.2% | $224.9M-3.9% | $234.1M+5.9% | $221.1M-7.0% | $237.7M+2.8% | $231.2M-3.3% | $239.2M |
| Goodwill | $806.9M0.0% | $807.0M0.0% | $806.9M0.0% | $806.9M+0.2% | $805.7M0.0% | $805.4M-0.2% | $806.9M+0.1% | $806.2M |
| Total Liabilities | $1.3B+0.4% | $1.3B-1.6% | $1.3B-0.9% | $1.3B+0.4% | $1.3B-1.8% | $1.3B-2.8% | $1.4B-1.5% | $1.4B |
| Current Liabilities | $292.7M-7.1% | $315.0M+0.1% | $314.7M+6.7% | $294.8M+4.1% | $283.1M+1.8% | $278.1M-1.5% | $282.3M+6.0% | $266.4M |
| Long-Term Debt | $25.0M-97.0% | $834.2M-2.2% | $853.0M-3.2% | $881.1M-1.2% | $891.4M-1.5% | $905.1M-3.7% | $940.1M-2.6% | $965.2M |
| Total Equity | $1.0B-1.5% | $1.0B+2.5% | $1.0B+0.5% | $1.0B+2.6% | $977.6M+1.6% | $962.7M+3.2% | $932.9M+5.8% | $881.8M |
| Retained Earnings | $602.6M+2.3% | $588.8M+2.9% | $572.0M-0.6% | $575.4M+2.7% | $560.1M0.0% | $560.3M+5.2% | $532.7M+8.7% | $489.9M |
CNMD Cash Flow Statement
| Metric | Q2'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $13.5M-70.9% | $46.3M-13.7% | $53.7M+84.3% | $29.1M-29.9% | $41.5M-4.2% | $43.3M-15.4% | $51.2M+18.2% | $43.3M |
| Capital Expenditures | $2.9M-43.4% | $5.1M-1.5% | $5.2M-9.5% | $5.7M+51.6% | $3.8M-6.5% | $4.0M+18.2% | $3.4M-4.8% | $3.6M |
| Free Cash Flow | $10.6M-74.3% | $41.2M-15.0% | $48.5M+107.2% | $23.4M-38.0% | $37.8M-3.9% | $39.3M-17.8% | $47.8M+20.3% | $39.7M |
| Investing Cash Flow | $4.1M+157.8% | -$7.1M-37.1% | -$5.2M+9.5% | -$5.7M-95.6% | -$2.9M+27.5% | -$4.0M-18.2% | -$3.4M+4.8% | -$3.6M |
| Financing Cash Flow | -$22.6M+39.6% | -$37.4M+14.1% | -$43.5M-64.1% | -$26.5M+6.6% | -$28.4M+44.4% | -$51.1M-31.5% | -$38.8M+11.9% | -$44.1M |
| Dividends Paid | $6.2M-0.2% | $6.2M0.0% | $6.2M0.0% | $6.2M+0.1% | $6.2M0.0% | $6.2M+0.2% | $6.2M+0.1% | $6.2M |
| Share Buybacks | $37.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CNMD Financial Ratios
| Metric | Q2'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.9%-0.6pp | 58.5%+9.3pp | 49.2%-5.9pp | 55.0%-0.3pp | 55.3%-2.0pp | 57.3%+0.8pp | 56.5%+1.2pp | 55.3% |
| Operating Margin | 8.0%-1.8pp | 9.8%+6.3pp | 3.5%-7.6pp | 11.2%+6.2pp | 5.0%-10.2pp | 15.2%-5.6pp | 20.8%+6.6pp | 14.2% |
| Net Margin | 4.4%-0.1pp | 4.5%+3.6pp | 0.9%-5.4pp | 6.3%+4.4pp | 1.9%-7.9pp | 9.8%-5.7pp | 15.5%+6.4pp | 9.0% |
| Return on Equity | 1.4%-0.3pp | 1.6%+1.3pp | 0.3%-1.9pp | 2.1%+1.5pp | 0.6%-2.9pp | 3.5%-1.7pp | 5.3%+1.8pp | 3.4% |
| Return on Assets | 0.6%-0.1pp | 0.7%+0.6pp | 0.1%-0.8pp | 0.9%+0.7pp | 0.3%-1.2pp | 1.5%-0.7pp | 2.1%+0.8pp | 1.3% |
| Current Ratio | 2.29+0.2 | 2.14+0.0 | 2.10-0.1 | 2.23-0.0 | 2.26-0.0 | 2.30+0.0 | 2.27-0.1 | 2.34 |
| Debt-to-Equity | 0.02-0.8 | 0.81-0.0 | 0.85-0.0 | 0.88-0.0 | 0.91-0.0 | 0.94-0.1 | 1.01-0.1 | 1.09 |
| FCF Margin | 3.3%-7.7pp | 11.1%-3.3pp | 14.3%+7.5pp | 6.8%-4.9pp | 11.8%+0.4pp | 11.4%-3.7pp | 15.1%+3.1pp | 12.0% |
Similar Companies
Frequently Asked Questions
What is Conmed Corp's annual revenue?
Conmed Corp (CNMD) reported $1.4B in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Conmed Corp's revenue growing?
Conmed Corp (CNMD) revenue grew by 5.2% year-over-year, from $1.3B to $1.4B in fiscal year 2025.
Is Conmed Corp profitable?
Yes, Conmed Corp (CNMD) reported a net income of $47.1M in fiscal year 2025, with a net profit margin of 3.4%.
What is Conmed Corp's EBITDA?
Conmed Corp (CNMD) had EBITDA of $155.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Conmed Corp have?
As of fiscal year 2025, Conmed Corp (CNMD) had $38.9M in cash and equivalents against $834.2M in long-term debt.
What is Conmed Corp's gross margin?
Conmed Corp (CNMD) had a gross margin of 54.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Conmed Corp's operating margin?
Conmed Corp (CNMD) had an operating margin of 7.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Conmed Corp's net profit margin?
Conmed Corp (CNMD) had a net profit margin of 3.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Conmed Corp pay dividends?
Yes, Conmed Corp (CNMD) paid $0.60 per share in dividends during fiscal year 2025.
What is Conmed Corp's return on equity (ROE)?
Conmed Corp (CNMD) has a return on equity of 4.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Conmed Corp's free cash flow?
Conmed Corp (CNMD) generated $150.9M in free cash flow during fiscal year 2025. This represents a -2.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Conmed Corp's operating cash flow?
Conmed Corp (CNMD) generated $170.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Conmed Corp's total assets?
Conmed Corp (CNMD) had $2.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Conmed Corp's capital expenditures?
Conmed Corp (CNMD) invested $19.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Conmed Corp spend on research and development?
Conmed Corp (CNMD) invested $55.9M in research and development during fiscal year 2025.
What is Conmed Corp's current ratio?
Conmed Corp (CNMD) had a current ratio of 2.10 as of fiscal year 2025, which is generally considered healthy.
What is Conmed Corp's debt-to-equity ratio?
Conmed Corp (CNMD) had a debt-to-equity ratio of 0.85 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Conmed Corp's return on assets (ROA)?
Conmed Corp (CNMD) had a return on assets of 2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Conmed Corp's Altman Z-Score?
Conmed Corp (CNMD) has an Altman Z-Score of 1.85, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Conmed Corp's Piotroski F-Score?
Conmed Corp (CNMD) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Conmed Corp's earnings high quality?
Conmed Corp (CNMD) has an earnings quality ratio of 3.62x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Conmed Corp cover its interest payments?
Conmed Corp (CNMD) has an interest coverage ratio of 3.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Conmed Corp?
Conmed Corp (CNMD) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.